

1. A method for inducing an immune response against transformed, infected or diseased tissue comprising

removing components present in the blood having a molecular weight of 120,000 daltons or less, until the transformed, infected, or diseased tissue is reduced in amount.

- 2. The method of claim 1 wherein the tissue is a solid tumor.
- 3. The method of claim 1 wherein the components are removed from one blood volume.
- 4. The method of claim 1 wherein the components are removed in multiple treatments.
- 5. The method of claim 1 further comprising treating the tissue with an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
- 6. The method of claim 5 wherein the agent is a cytokine and the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-CSF and SCF.
- 7. The method of claim 1 further comprising selectively removing soluble TNF receptor 1 and receptor 2 molecules.
- 8. The method of claim 1 further comprising vaccinating the patient with a vaccine against the transformed, infected or diseased tissue.
- 9. A system for inducing an immune response against transformed, infected or diseased tissue comprising

a device for removing components present in the blood having a molecular weight of 120,000 daltons or less, and

an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.

Subbi/

16

- 10. The system of claim 9 wherein the agent is an anti-angiogenic compound.
- 11. The system of claim 9 wherein the agent is a procoagulant compound.
- 12. The system of claim 9 wherein the agent is a cytokine.
- 13. The system of claim 12 wherein the agent is a cytokine and the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-QSF and SCF.
- 14. The system of claim 9 wherein the agent is a chemotherapeutic agent.
- 15. The system of claim 14 wherein the agent is selected from the group consisting of alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol.
- 16. The system of claim 9 wherein the device includes means for administering radiation to the tissue.

